Organization | National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA) Report issue

Government Phase 1 Phase 2 Phase 3 Phase 4

Founded: Bethesda MD United States (1970)

Organization Overview

First Clinical Trial

1992

NCT00000456

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Vijay Ramchandani, Ph.D.

Active Ingredients

Drugs in Phase 4 Trials (27)

acamprosate (campral) (8 trials)

buprenorphine (1 trial)

bupropion (wellbutrin) (8 trials)

carbamazepine (tegretol) (1 trial)

citalopram (celexa) (3 trials)

clozapine (clozaril) (1 trial)

disulfiram (antabuse) (2 trials)

dutasteride (avodart) (5 trials)

emtricitabine (emtriva) (1 trial)

engerix-b (1 trial)

fluoxetine (prozac) (4 trials)

hepatitis a vaccine, inactivated (vaqta) (2 trials)

hepatitis b vaccine (recombinant) (recombivax) (3 trials)

lamotrigine (lamictal) (2 trials)

lorazepam (ativan) (5 trials)

methadone (methadose) (1 trial)

methylphenidate (ritalin) (5 trials)

naloxone (narcan) (1 trial)

naltrexone (revia) (48 trials)

nicotine (nicorette) (8 trials)

oxytocin (syntocinon) (7 trials)

paroxetine (paxil) (1 trial)

quetiapine (seroquel) (3 trials)

sertraline (zoloft) (7 trials)

tenofovir (viread) (1 trial)

topiramate (topamax) (11 trials)

zonisamide (Zonegran) (3 trials)

Drugs in Phase 3 Trials (16)

anakinra (kineret) (2 trials)

aripiprazole (abilify) (4 trials)

ethanol (22 trials)

gabapentin (neurontin) (8 trials)

ketamine (ketalar) (2 trials)

kudzu extract (2 trials)

methylprednisolone (medrol) (1 trial)

ondansetron (zofran) (10 trials)

pentoxifylline (trental) (1 trial)

pregabalin (lyrica) (2 trials)

(r)-3-hydroxybutyl (r)-3-hydroxybutyrate (1 trial)

s-adenosyl methionine (1 trial)

ulexin (1 trial)

varenicline (chantix) (11 trials)

venlafaxine (effexor) (1 trial)

zinc dichloride (2 trials)

Drugs in Phase 2 Trials (65)

abt-436 (1 trial)

acetylcysteine (mucomyst) (4 trials)

allogeneic bone marrow derived mesenchymal stem cell (1 trial)

ans-6637 (1 trial)

apremilast (otezla) (1 trial)

aprepitant (Emend) (1 trial)

asp8062 (1 trial)

atomoxetine (strattera) (4 trials)

baclofen (lioresal) (1 trial)

brexpiprazole (rexulti) (1 trial)

choline bitartrate (1 trial)

choline c11 (choline c-11) (1 trial)

cort118335 (1 trial)

dextrose (1 trial)

donepezil (aricept) (1 trial)

doxazosin (cardura) (2 trials)

dronabinol (marinol) (1 trial)

duloxetine (Cymbalta) (2 trials)

dur-928 (1 trial)

emricasan (1 trial)

endotoxin (1 trial)

fenofibrate (fenoglide) (1 trial)

filgrastim (neupogen) (2 trials)

get 73 (1 trial)

ghrelin (1 trial)

glwl-01 (1 trial)

guanfacine (tenex) (2 trials)

hyperimmune bovine colostrum (1 trial)

icosapent ethyl (vascepa) (2 trials)

interferon alpha-2b (Intron-A) (1 trial)

lactobacillus rhamnosus (2 trials)

levetiracetam (keppra) (2 trials)

m-chlorophenylpiperazine (1 trial)

memantine (namenda) (3 trials)

metadoxine (1 trial)

Methoxypregnenolone (1 trial)

mifepristone (mifeprex) (3 trials)

mirtazapine (remeron) (1 trial)

morphine (1 trial)

mycophenolate (myfortic) (1 trial)

nalmefene (revex) (2 trials)

obeticholic acid (ocaliva) (2 trials)

perampanel (fycompa) (1 trial)

pexacerfont (1 trial)

pf-5190457 (2 trials)

pioglitazone (actos) (4 trials)

polyene phosphatidylcholine (1 trial)

prazosin (minipress) (6 trials)

prednisone (meticorten) (2 trials)

propranolol (inderal) (2 trials)

ribavirin (virazole) (1 trial)

rilonacept (arcalyst) (1 trial)

rimonabant (1 trial)

safflower oil (1 trial)

semaglutide (Ozempic) (1 trial)

sodium chloride (1 trial)

suvorexant (belsomra) (1 trial)

tolcapone (tasmar) (1 trial)

tradipitant (1 trial)

trazodone (desyrel) (1 trial)

valproic acid (depakene) (1 trial)

verucerfont (1 trial)

vitamin c (1 trial)

yohimbine (1 trial)

Drugs in Phase 1 Trials (18)

alirocumab (praluent) (1 trial)

brexanolone (Zulresso) (1 trial)

efalex (1 trial)

exenatide (byetta) (1 trial)

florbetaben F-18 (neuraceq) (1 trial)

fludeoxyglucose f-18 (2 trials)

ibudilast (1 trial)

lacosamide (vimpat) (1 trial)

minocycline (minocin) (1 trial)

nop-1a (1 trial)

pbr28 (1 trial)

pitolisant (Wakix) (1 trial)

pittsburgh compound b (1 trial)

pregnenolone (1 trial)

raclopride (1 trial)

saracatinib (1 trial)

thalidomide (Thalomid) (1 trial)

vlx103 (1 trial)

Drugs in Other Trials (13)

caffeine (1 trial)

chlorzoxazone (parafon forte dsc) (1 trial)

corn oil (1 trial)

cycloserine (seromycin) (1 trial)

diphenhydramine (benadryl) (1 trial)

docosahexaenoic acid (1 trial)

linolic acid (1 trial)

multivitamins (1 trial)

purple grape juice (1 trial)

soybean oil (1 trial)

(s,s)-[11c]mrb (1 trial)

white wine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 3)

Alcohol Drinking (Phase 4)

Alcoholic Intoxication (Phase 4)

Alcohol-Induced Disorders (Phase 4)

Alcoholism (Phase 4)

Alcohol-Related Disorders (Phase 4)

Anxiety Disorders (Phase 4)

Attention Deficit Disorder with Hyperactivity (Phase 4)

Behavior, Addictive (Phase 4)

Binge Drinking (Phase 2)

Bipolar Disorder (Phase 4)

Brain Injuries (Phase 2)

Brain Injuries, Traumatic (Phase 2)

Chemically-Induced Disorders (Phase 1)

Chronic Pain (Phase 4)

Cocaine-Related Disorders (Phase 2)

Cognition Disorders (Phase 1)

Cognitive Dysfunction (Phase 2)

Depression (Phase 4)

Depressive Disorder (Phase 4)

Depressive Disorder, Major (Phase 2)

Disease (Phase 4)

Drinking Behavior (Phase 2)

Dyssomnias (Phase 2)

Emergencies (Phase 4)

Encephalitis (Phase 1)

Fatty Liver (Phase 1)

Fatty Liver, Alcoholic (Phase 1)

Feeding and Eating Disorders (Phase 4)

Fetal Alcohol Spectrum Disorders (Phase 2)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis, Alcoholic (Phase 3)

Hepatitis B (Phase 4)

Hepatitis C (Phase 2)

HIV Infections (Phase 4)

Hypersensitivity (Phase 1)

Infections (Phase 4)

Inflammation (Phase 2)

Insulin Resistance (Phase 2)

Liver Diseases (Phase 3)

Liver Diseases, Alcoholic (Phase 3)

Marijuana Abuse (Phase 2)

Mental Disorders (Phase 4)

Neurobehavioral Manifestations (Phase 2)

Neurocognitive Disorders (Phase 1)

Neurodevelopmental Disorders (Phase 2)

Opioid-Related Disorders (Phase 4)

Pancreatitis (Phase 2)

Pancreatitis, Chronic (Phase 2)

Parasomnias (Phase 2)

Pathologic Processes (Phase 1)

Phobia, Social (Phase 4)

Psychotic Disorders (Phase 4)

Schizophrenia (Phase 4)

Sepsis (Phase 2)

Sleep Wake Disorders (Phase 2)

Stress Disorders, Post-Traumatic (Phase 4)

Stress Disorders, Traumatic (Phase 4)

Substance-Related Disorders (Phase 4)

Substance Withdrawal Syndrome (Phase 4)

Syndrome (Phase 2)

Tobacco Use Disorder (Phase 4)

Toxemia (Phase 2)

Underage Drinking (Phase 2)

Weight Gain (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 266
# of Trial APIs: 139